Vol. 4, Issue 12 (2018)
Study of comparative evaluation of Atorvastatin and Salacinol (Salacia roxburghii) on BMI, Lipid profile and adiponectin in patient of chronic kidney disease with hypertension
Author(s): Dr. Manish Kumar Bhaskar, Dr. RG Singh
Abstract: Hippocrates in 5th century B.C blamed malfunctioning kidney tor certain signs and symptoms. Progression of renal failure is an area of Nephrology where our understanding has improved appreciably in the last century but still our knowledge is like a drop in ocean. Progression of renal failure is an area of Nephrology where our understanding has improved appreciably in the last century but still our knowledge is like a drop in ocean. We have ample of evidence that progression of renal failure can be slowed down but we still need more definite information whether established renal failure can be reversed. Retarding the progression of renal failure is one of the most important task for the nephrologists as it not only improves the quality of life of the patient but also delays the development of end stage renal disease. This pilot clinical study was planned to explore the therapeutic potential of salacinol on BMI, Lipid profile and Adiponectin. Objectives: To study of comparative evaluation of atorvastatin and salacinol (Salacia roxburghii) on BMI, Lipid profile and Adiponectin in patient of chronic kidney disease with hypertension Methods: The present study was conducted in the Department of General medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi. Eighty patients of mild to moderate stable chronic renal failure with hypertension attending Nephrology OPD were admitted in Nephrology ward from May 2015 to June 2016 were included in the study. Initially patients were explained in detail about the experimental nature of the drugs and plan of study and only willing patient were included in the study after signing of the written consent. Before starting the drugs a through history was taken and clinical examination was done. The patients were then subjected to baseline urine, hematological, biochemical and immunological investigation. Results: Overall 80 patients completed the six months follow-up and were finally included in the study. Atorvastatin and Salacinol group finally had 40 patients and there were 40 patients in Atorvastatin group. Age of patient ranged from 20 years onwards. Mean age of patient in various group were well matched & there was no significant statistical differences. Mean age of group-I was 53.9 yrs & Mean age of Group-II was 51.75 Yrs. There was male preponderance in our patient. Overall 65% patients were male & 35% were female. In Group-1 623% patient were male while in Group-II 67.5% were male. Mean body mass index in Group-I & Group-II at baseline were 25.9±2.3 & 26.7±1.7 & on subsequent follow up at three and six months were statistically significant. LDL/HDL ratio at baseline in Group-I & Group-II were 4.35±0.50 & 4.44±0.53 respectively changes were statistically significant on subsequent visit at three and six months on intergroup comparison changes were statistically significant at the end of three months & six months probably of hypolipidemic role of salacinol. Similarly serum cholesterol value comparison in intergroup, changes were statistically significant at three & six months. Mean Adiponectin level at baseline in group-I and Group-II were 5.29 and 4.25 respectively and changes were statistically significant at three and six months in group-I while at six months in Group-II. On intergroup comparison were statistically significant at three and six months. On intergroup changes baseline comparison, changes were also statistically significant. Conclusion: The male patients dominated over the female patients with a male to female ratio of 2:1. Age of the patient ranged from 20yrs onward. Majority of the patient were above 40yrs of age. Commonest symptom was weakness in all the groups followed by anorexia, swelling over body, pallor & sleep disorders. In patient treated with Atorvastatin and Salacinol BMI (Body mass index) showed significant decrease (<0.05) on 3rd and six months. Patient treated with Atorvastatin and Salacinol, lipid profile including LDL/HDI, ratio, serum total cholesterol & triglyceride showed significant decrease (<0.05) at three months and at the end of study. In patient treated with Atorvastatin and salacinol, the changes in Adiponectin level were statistically significant (<().()()l) at three and six months.